Strawberry Cough (CBD): A Comprehensive Strain Guide

Overview

Strawberry Cough (CBD) is a CBD-forward expression of the classic, fruit-scented Strawberry Cough lineage, crafted to deliver the berry aromatics and daytime clarity of the original with far lower intoxication potential. Where the original Strawberry Cough is commonly associated with terpinolene-driven brightness and moderate THC, this CBD phenotype shifts the chemotype toward cannabidiol as the dominant cannabinoid. The result is a cultivar that many consumers choose for focus, social ease, and functional calm, frequently used during daytime without the heavy psychoactivity associated with high-THC sativas.

In dispensaries and seed catalogs, you may see this cultivar labeled Strawberry Cough CBD, Strawberry Cough (CBD), or Strawberry CBD depending on breeder and THC:CBD ratio. Chemovars sold under this name can vary: some are CBD-dominant with THC under 1%, while others are balanced 1:1 types with roughly equal THC and CBD. Because naming conventions are inconsistent across markets, always rely on the certificate of analysis (COA) to confirm cannabinoid and terpene content before purchase.

This article focuses on the CBD-leaning profiles commonly found in Strawberry Cough (CBD) releases. It covers the history and breeding logic behind the CBD version, details on its aroma and flavor chemistry, and a deep dive into cannabinoid and terpene data trends. You will also find an extensive cultivation guide tailored to maximizing the berry-forward bouquet and consistent CBD expression that define this modern take on a beloved classic.

History and Origin

The original Strawberry Cough earned its reputation in the early 2000s, popularized by breeder and cultivator Kyle Kushman. The story often cited in industry lore describes a gifted clone with a pronounced strawberry scent, likely influenced by Haze ancestry, that spread from the Northeast United States to California’s medical market. Over time, the strain’s uplifting, clear-headed effects and sweet fragrance made it a fixture in dispensary menus and connoisseur gardens.

The CBD-forward variant emerged a decade later as breeders started selectively crossing popular terpene-rich cultivars with high-CBD donor lines. As consumer demand for low-intoxication cannabis rose after 2014–2018, particularly with the mainstreaming of CBD and the 2018 U.S. Farm Bill, seed companies produced CBD versions of familiar names to marry recognizable flavor with gentler effects. Strawberry Cough, prized for its bright terpinolene bouquet and approachable sativa lift, was a prime candidate for this treatment.

Breeders typically worked from clone-only Strawberry Cough or seed-based facsimiles, introducing CBD through parents like Cannatonic, AC/DC, or CBD Crew selections, then backcrossing to restore the strawberry-forward character. By the late 2010s, Strawberry Cough (CBD) offerings began appearing in both adult-use and hemp-adjacent markets, often with THC:CBD ratios ranging from 1:2 to 1:20. The result is a family of cultivars that retain the signature berry nose while reducing intoxication for broader daytime utility.

Genetic Lineage and Breeding Notes

While the original Strawberry Cough has an uncertain pedigree, it is frequently associated with Haze or Haze-like ancestry and a strawberry-scented parent sometimes referenced as Strawberry Fields or Erdbeer-type genetics. Most CBD versions are not simple replicas; they are deliberate crosses with CBD-rich donor lines. The breeder goal is to preserve the cultivar’s terpinolene-pinene-myracene strawberry profile while shifting the chemotype toward elevated CBD.

CBD donor lines commonly used across the industry include Cannatonic (frequently producing 1:1 offspring), AC/DC (known for very high CBD and minimal THC), and CBD Crew male lines that reliably transmit CBD synthase alleles. Depending on how breeders backcross or select, Strawberry Cough (CBD) can express as a balanced 1:1 or as a CBD-dominant chemotype with THC below 1–5%. Stabilization typically requires multiple filial generations and selection from large populations to lock in both flavor and chemotype.

Growers should understand that genotype does not guarantee chemotype; environmental factors and harvest timing can subtly shift THC:CBD ratios. Nonetheless, skillful breeding with verified CBD parents and rigorous lab selection can deliver consistent CBD expressions across seed lots. When shopping for genetics, look for breeders who publish third-party lab data across multiple phenotypes and generations to confirm reliability.

Appearance and Structure

Strawberry Cough (CBD) typically exhibits a sativa-forward structure with elongated, spearlike colas and moderately spaced internodes. The buds are often conical and medium density rather than rock-hard, which improves airflow in the canopy and reduces susceptibility to botrytis in humid climates. Expect vibrant lime to forest-green calyxes, prominent orange pistils, and a frosty trichome layer that can appear silvery under LED lighting.

Leaves tend to be slender with serrations that speak to the sativa influence, and plants can stretch 1.5–2.0x after transition to flowering. Under strong, full-spectrum light, anthocyanin expression is modest in most phenotypes, with only occasional rose or magenta hints near bracts late in bloom. The overall bag appeal hinges on the resin sheen and the striking contrast between orange pistils and bright green calyxes.

Mature inflorescences display a high calyx-to-leaf ratio compared to many CBD cultivars, easing trimming and improving finished appearance. Trichome heads are typically abundant and bulbous, with a good proportion of capitate-stalked trichomes visible even to the naked eye. When properly dried and cured, bud surfaces remain slightly tacky, a sign of preserved terpenes and resins that enhances aroma on break-up.

Aroma

True to the name, Strawberry Cough (CBD) leans into sweet, fresh berry notes on first inhale from the jar. The top notes evoke ripe strawberries, strawberry jam, and wild berries, often accented by a faint citrus zest. On deeper nose, you may pick up hints of pine, green apple, and a subtle peppery spice that provides depth and prevents the bouquet from becoming cloying.

The strawberry character likely arises from a blend of terpenes and minor volatile compounds rather than a single molecule. Terpinolene, ocimene, and myrcene often coordinate to create the sweet, fruity backbone, while pinene brightens and caryophyllene adds a pepper-spice undertone. In market samples of Strawberry Cough-type cultivars, total terpene content typically ranges from 1.0% to 3.0% by weight, with standout phenotypes exceeding 3.5% under careful cultivation and curing.

Cracking a bud releases a stronger strawberry-candy impression as oxygen liberates volatiles from the resin heads. Freshly ground flower can reveal a greener, slightly herbal streak that dissipates quickly in the air. Aroma intensity correlates with total terpene percentage; samples above 2% terpenes generally project more vivid berry aromatics on both cold and warm nose.

Flavor

On the palate, Strawberry Cough (CBD) delivers a clear strawberry top note reminiscent of strawberry gummies and fresh jam. The inhale is bright and slightly effervescent, with a citrus-sparkle quality often associated with terpinolene-rich cultivars. The exhale brings a light pine and pepper finish, likely from alpha-pinene and beta-caryophyllene, which balances the sweetness and prevents palate fatigue.

Vaporization at 180–190 C tends to emphasize sweetness and berry nuance, while higher temperatures (200–210 C) draw out the herbal-spice base and a faint earthiness. In joints or bowls, the first two puffs are typically the most strawberry-forward, with the character softening by mid-session as resin heats. Concentrates made from CBD-dominant Strawberry Cough often capture the berry profile if produced with low-temperature extraction that preserves monoterpenes.

Water-cured or overdried buds lose much of the delicate top-note sweetness, so proper humidity during storage is essential for flavor fidelity. When cured slowly to 10–12% moisture content and stored around 58–62% relative humidity, the berry-and-zest flavor remains vivid for months. Consumers often report that the flavor correlates strongly with mood uplift and perceived freshness, making it a favorite for early day sessions.

Cannabinoid Profile and Ratios

Because Strawberry Cough (CBD) is a category rather than a single stabilized clone, cannabinoid ratios vary by breeder and phenotype. Common retail profiles fall into three bands: CBD-dominant (CBD 8–18% with THC 0.3–5%), balanced 1:1 (CBD and THC each in the 6–12% range), and low-THC hemp-compliant versions (CBD 8–12% with total THC below 0.3% by dry weight). Across legal markets, flower labeled as CBD-dominant typically clusters around CBD 10–16% with THC 0.5–3%.

Inhalation delivers cannabinoids rapidly, with onset usually within 1–3 minutes and peak effects around 10–30 minutes post-inhalation. For most users, functional effects persist 2–4 hours with inhaled CBD-dominant flower, though subjective duration depends on dose, food intake, and tolerance. Oral routes produce slower onset (30–120 minutes) and longer duration (6–8 hours), which can be useful for sustained relief but less appropriate for instant effect.

Beyond THC and CBD, minor cannabinoids like CBG (0.2–1.0%), CBC (0.1–0.5%), and trace THCV are occasionally detected in Strawberry Cough (CBD) lab reports. While present in smaller amounts, these compounds may subtly influence the effect profile through receptor modulation and entourage effects. Always consult the batch-specific COA for exact percentages, as minor cannabinoids fluctuate substantially with genetics, maturity at harvest, and post-harvest handling.

Terpene Profile and Chemistry

Strawberry Cough (CBD) often mirrors the original’s terpinolene-forward signature, though CBD crosses can shift dominance. In lab-tested samples of Strawberry Cough-type cultivars across several markets, terpinolene frequently appears within the 0.2–0.9% range by weight, supported by alpha-pinene (0.15–0.6%), beta-myrcene (0.2–0.8%), and beta-caryophyllene (0.2–0.7%). Ocimene (0.1–0.5%) and limonene (0.1–0.4%) commonly fill out the sweet, citrusy top end.

Terpinolene is associated with bright, uplifting aromatic character and is prevalent in many classic sativa-leaning chemovars. Alpha-pinene contributes pine and a sense of mental clarity, while beta-caryophyllene provides a peppered warmth and is notable for selectively binding CB2 receptors in the endocannabinoid system. Myrcene can soften the blend with a fruity-musk tone and may influence perceived body relaxation in higher concentrations.

Total terpene content in well-grown, gently cured Strawberry Cough (CBD) typically reaches 1.5–2.5%, with top-shelf batches surpassing 3%. Storage conditions strongly impact terpene retention; studies show monoterpenes can degrade by 30–50% over six months at room temperature with light exposure. Producers aiming for maximum strawberry aromatics prioritize low-temperature drying, stable humidity, and opaque, oxygen-limiting packaging to preserve volatile compounds.

Experiential Effects and Use Cases

Most users describe Strawberry Cough (CBD) as clear-headed, calm, and socially friendly. The cultivar tends to reduce mental clutter and somatic tension without the pronounced euphoria or time dilation that can accompany high-THC sativas. Many report improved focus and a subtle mood lift, making it suitable for daytime creativity, conversation, or light exercise.

Onset is quick with inhalation and is characterized by a gentle chest expansion and a noticeable easing of mental chatter within minutes. Some users note a paradoxical micro-cough on the first pull, likely due to terpinolene and pinene volatiles, which is part of the original cultivar’s lore. Unlike its THC-heavy relatives, the CBD-dominant phenotype rarely induces racing thoughts, making it approachable for novice consumers.

At higher doses, CBD can introduce mild sedation or a soft heaviness behind the eyes, particularly in evening sessions. Balanced 1:1 versions will feel more intoxicating, with a brighter headspace akin to a light sativa but tempered by CBD’s modulating influence. Individual responses vary; factors like tolerance, recent meals, and concurrent caffeine intake can significantly shape perceived effects.

Potential Medical Uses and Evidence Summary

While Strawberry Cough (CBD) is not an FDA-approved therapy, its CBD-forward chemistry aligns with an evidence base suggesting potential benefits for anxiety, seizure disorders, inflammation, and sleep quality. Randomized trials of purified CBD (Epidiolex) in treatment-resistant pediatric epilepsies demonstrate median seizure reductions of 37–44% over baseline at doses of 10–20 mg/kg/day, with responder rates (≥50% reduction) in approximately 40% of patients. These results do not translate directly to inhaled flower, but they illustrate CBD’s anticonvulsant potential.

For anxiety, several human studies indicate acute anxiolytic effects at moderate to high oral doses. In a 2011 public speaking test study, 600 mg of CBD reduced anxiety in participants with social anxiety disorder compared to placebo. A 2019 open-label trial in a psychiatric clinic observed anxiety score reductions in 79% of patients after one month using daily CBD, with most participants taking 25–50 mg/day; fatigue and sedation were the most common adverse effects.

CBD’s anti-inflammatory potential has been documented in preclinical models via modulation of cytokine signaling, TRPV1 activity, and oxidative stress pathways. Small clinical trials and observational studies suggest benefit in certain pain conditions when CBD is combined with THC in roughly 1:1 ratios, improving pain interference and sleep quality. For sleep, low-to-moderate CBD doses can either promote sleep or enhance daytime alertness depending on timing and dose; user reports with Strawberry Cough (CBD) often cite better sleep onset when consumed in the evening, particularly in balanced 1:1 batches.

Safety profiles for CBD are generally favorable, though interactions with CYP450 enzymes can affect metabolism of drugs like warfarin or certain anticonvulsants. Common side effects include dry mouth, fatigue, diarrhea, and changes in appetite, typically mild to moderate and dose-dependent. Individuals considering CBD for health reasons should review batch COAs for cannabinoid ratios and consult a healthcare professional, especially when using other medications or managing chronic conditions.

Comprehensive Cultivation Guide

Strawberry Cough (CBD) grows best in environments that mirror sativa-leaning preferences: ample light, good airflow, and steady nutrition without heavy nitrogen late in flower. Indoors, a 5–7 week vegetative period under 18–20 hours of light produces vigorous canopies; expect 1.5–2.0x stretch during the first 2–3 weeks after switching to 12/12. Optimal canopy temperatures range 24–27 C in veg and 22–26 C in flower, with nighttime drops of 2–4 C to enhance color and terpene retention.

Aim for VPD around 0.8–1.2 kPa in veg and 1.2–1.5 kPa in flower. Relative humidity around 60–65% in veg and 45–55% in flower helps manage transpiration without inviting powdery mildew. Under modern LED fixtures, target 500–700 µmol/m2/s PPFD in late veg and 700–900 µmol/m2/s in mid-to-late flower; with added CO2 at 800–1,200 ppm, PPFD can be pushed toward 1,000–1,100 µmol/m2/s to increase yield by 10–20% when other parameters are dialed.

Soil and soilless media both work well. In soil, maintain pH 6.2–6.8; in coco or hydro, keep pH 5.7–6.2. Electrical conductivity (EC) targets of 1.2–1.6 mS/cm in veg and 1.6–2.0 mS/cm in flower are typical, with experienced growers pushing slightly higher during peak bloom if plants show no tip burn.

Use a balanced vegetative formula around 3-1-2 N-P-K, then transition to a bloom formula near 1-3-2